β受体阻滞剂在慢性阻塞性肺疾病合并心血管疾病中的治疗进展  

Progress inβreceptor-blocker treatment in chronic obstructive pulmonary disease complicated with cardiovascular diseases

作　　者：岳雨倩 陈复辉[1] YUE Yu-qian;CHEN Fu-hui(Department of Respiratory Medicine,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院呼吸内科,黑龙江哈尔滨150081

出　　处：《心血管康复医学杂志》2024年第3期361-364,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：β受体阻滞剂是治疗心血管疾病(CVD)的药物,而β受体激动剂用于治疗慢性阻塞性肺疾病(COPD),两种药物作用机制相反。但COPD与CVD二者联系密切,CVD与肺功能障碍的严重程度相关。β受体阻滞剂用于COPD的争议不断,但研究表明,心脏选择性β受体阻滞剂可以降低轻、中度COPD合并CVD的死亡率,且可降低COPD加重的风险,而非选择性β受体阻滞剂则会增加COPD加重的风险。但是在COPD合并CVD患者中使用心脏选择性β受体阻滞剂的剂量,及与β受体激动剂之间的平衡仍需要谨慎对待。研究新型的β受体阻滞剂更是未来需密切关注的问题。β-receptor blockers are used to treat cardiovascular disease(CVD),whileβ-receptor agonists are used to treat chronic obstructive pulmonary disease(COPD).The two drugs have opposite mechanisms of action.However,there is a close relationship between COPD and CVD,and CVD is related to the severity of pulmonary dysfunction.The use ofβ-receptor blockers in COPD is still controversial,but studies have shown that cardiac selectiveβ-receptor blockers can reduce mortality in mild and moderate COPD with CVD and reduce the risk of COPD exacerbation,while non-selectiveβ-receptor blockers increase the risk of COPD exacerbation.However,the dosage of cardiac selectiveβ-receptor blockers and its balance withβ-receptor agonists in COPD patients with CVD still requires serious treatment.Research on newβ-receptor blockers is a problem to be paid close attention to in the future.

关 键 词：肺疾病 慢性阻塞性 心血管疾病 肾上腺素能Β受体拮抗剂 

分 类 号：R563.9[医药卫生—呼吸系统]